Adherex Technologies Inc.
TSX : AHX
AMEX : ADH

Adherex Technologies Inc.

April 17, 2007 08:30 ET

Adherex Announces Two Presentations of ADH-1 Data at 2007 American Association of Cancer Research Annual Meeting

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(CCNMatthews - April 17, 2007) - Adherex Technologies Inc. (TSX:AHX) (AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company will be presenting preclinical data on ADH-1 in combination with chemotherapy in a poster presentation at the 2007 Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles, CA, today from 1-5 p.m. PT entitled "Synergistic anti-tumor activity of ADH-1 in vitro and in vivo in combination with paclitaxel in ovarian cancer cell lines" by Mukur Gupta, Derrick Barnes, Jan Losos, Glenn Spehar, Mark Bednarcik, and William P. Peters.

This study explored in vitro and in vivo anti-tumor activity of ADH-1 alone, paclitaxel alone and ADH-1 and paclitaxel in combination using ovarian cell lines and ovarian cancer xenograft animal models. In vitro, ADH-1 was found to have a synergistic effect with paclitaxel in the ovarian cell lines. In vivo, the combination of ADH-1 and paclitaxel was found to have anti-tumor activity significantly superior to the untreated group and groups treated with single-agent ADH-1 alone or paclitaxel alone.

Additional data on ADH-1 is also being presented today at AACR in another poster presentation from 1-5 p.m. PT by Dr. Margaret Wheelock, Professor, Director, Nebraska Center for Cellular Signaling, University of Nebraska Medical Center, and her colleagues, entitled "ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression" by Yasushi Shintani, Keith R. Johnson and Margaret J. Wheelock, University of Nebraska Medical Center.

This study examined the in vitro effect of single-agent ADH-1 on N-cadherin mediated tumor cell scattering and migration, cell proliferation and apoptosis (cell death) in pancreatic cancer cells and the in vivo anti-tumor activity of single-agent ADH-1 in N-cadherin positive pancreatic cancer orthotopic animal models. In vitro, ADH-1 was found to prevent N-cadherin mediated cell scattering and migration and to induce apoptosis. In vivo, ADH-1 was found to prevent tumor growth and metastasis.

"These data are important additions to our understanding of ADH-1. The first study is another demonstration of the potential for synergistic anti-tumor effects when using ADH-1 in combination with chemotherapy, and has been important in the development of our clinical program combining ADH-1 and chemotherapy. The second study indicates single-agent ADH-1 activity in pancreatic cancer, an N-cadherin positive cancer model, with a particularly interesting anti-metastatic effect and important therapeutic implications," said William P. Peters, MD, PhD, Chairman and CEO of Adherex.

Adherex is currently conducting two clinical trials of ADH-1 in combination with chemotherapy. The first, which began in October 2006, is exploring ADH-1 in combination with three different anti-cancer chemotherapies (docetaxel, carboplatin and capecitabine). The second, which began in March 2007, is exploring the combination of systemic ADH-1 plus isolated limb infusion melphalan for the treatment of melanoma. Following the meeting, Adherex will make the posters presented at AACR available on its website at www.adherex.com.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at www.adherex.com.

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the development plans of the Company and the expected implications of the results of our development. We can provide no assurance that such development will proceed as currently anticipated or that the expected results of such development will be realized. We are subject to various risks, including the uncertainties of clinical trials, drug development and regulatory review, the early stage of our product candidates, our reliance on collaborative partners, our need for additional capital to fund our operations, our history of losses, and other risks inherent in the biopharmaceutical industry. For a more detailed discussion of related risk factors, please refer to our public filings available at www.sedar.com and www.sec.gov.

Contact Information